Risk factors associated with older age in treatment-naive HIV-positive patients

Intervirology

Volumn 55, Issue 2, 2012, Pages 147-153

  Reuter, Stefan ^a   Oette, Mark ^b   Kaiser, Rolf ^c   Lengauer, Thomas ^d   Fätkenheuer, Gerd ^c   Rockstroh, Jürgen K ^e   Knechten, Heribert ^f   Häussinger, Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Hospital Augustinerinnen   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f Private Practice   (Germany)

Author keywords

HIV late presenter; HIV transmission; HIV 1; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BISEXUALITY; CAUCASIAN; CD4 LYMPHOCYTE COUNT; ETHNICITY; FEMALE; GERMANY; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; ETHNIC GROUPS; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEX FACTORS; SEXUAL BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856414134     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000332014     Document Type: Article

References (39)

1. AI-graveS among persons aged greater than or equal to 50 years - United States, 1991-1996. Morb Mortal Wkly Rep 1998;47:21-27.
2. CASCA-graveE Collaboration: Differences in C-grave4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003;34:76-83.
3. Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
4. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur R-grave, Cavert WP, Henry WK, Neaton J-grave: C-grave4+ count and risk of non-AI-graveS diseases following initial treatment for HIV infection. AI-graveS 2008;22:841-848.
5. CASCA-graveE Collaboration: Differences in C-grave4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003;34:76-83.
6. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F: Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AI-graveS incidence. AI-graveS 2002;16:1945-1951.
7. Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, Rice B-grave, Evans BG: No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AI-graveS 2005;19:513-520.
8. Chiao EY, Ries KM, Sande MA: AI-graveS and the elderly. Clin Infect Dis 1999;28:740-745.
9. Clumeck N, Pozniak A, Raffi F: European AI-graveS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71.
10. Douek DC, McFarland R-grave, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson B-grave, Zack JA, Picker LJ, Koup RA: Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
11. el-Sadr W, Gettler J: Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med 1995;155:184-186.
12. Grabar S, Kousignian I, Sobel A, Le BP, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D: Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AI-graveS 2004;18:2029-2038.
13. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D: Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AI-graveS 2000;14:141-149.
14. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D: Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002;34:1530-1533.
15. Jansen K, Brockmeyer NH, Hahn M, Kaul I, Fenske S, Rausch M, Kuhlmann B, Ulmer A, Lauenroth-Mai E, Harrer T, Hower M, Skaletz-Rorowski A, Michalik C: Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AI-graveS. Eur J Med Res 2009;14:415-425.
16. Kalayjian RC, Landay A, Pollard RB, Taub D-grave, Gross BH, Francis IR, Sevin A, Pu M, Spritzler J, Chernoff M, Namkung A, Fox L, Martinez A, Waterman K, Fiscus SA, Sha B, Johnson D, Slater S, Rousseau F, Lederman MM: Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive C-grave8+ cell depletion, reduced expression of C-grave28 on C-grave8+ cells, and reduced thymic volumes. J Infect Dis 2003;187:1924-1933.
17. Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76.
18. Knobel H, Guelar A, Valldecillo G, Carmona A, Gonzalez A, Lopez-Colomes JL, Saballs P, Gimeno JL, Diez A: Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AI-graveS 2001;15:1591-1593.
19. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, Furrer H, Sterling T, Monforte A-grave, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D: Prognosis of patients treated with cART from 36 months after initiation, according to current and previous C-grave4 cell count and plasma HIV-1 RNA measurements. AI-graveS 2009;23:2199-2208.
20. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C: Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AI-graveS 2002;16:21-29.
21. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C: HIV-infected adults with a C-grave4 cell count greater than 500 cells/mm 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-77.
22. Mack KA, Ory MG: AI-graveS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr 2003;33(suppl 2): S68-S75.
23. Manfredi R, Chiodo F: A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIVinfected patients with advanced age. AI-graveS 2000;14:1475-1477.
24. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio MA, Schmeisser N, Staszewski S, Egger M: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AI-graveS 2007;21:1185-1197.
25. Oette M, Reuter S, Kaiser R, Lengauer T, Fätkenheuer G, Knechten H, Hower M, Pfister H, Häussinger D, RESINA Study Group: Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA Study 2001-2009. Intervirology 2012;55:154-159.
26. Orchi N, Balzano R, Scognamiglio P, Navarra A, De Carli G, Elia P, Grisetti S, Sampaolesi A, Giuliani M, De Filippis A, Puro V, Ippolito G, Girardi E: Ageing with HIV: newly diagnosed older adults in Italy. AI-graveS Care 2008;20:419-425.
27. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren J-grave, Clotet B: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSI-graveA study. Arch Intern Med 2000;160:1123-1132.
28. Perez JL, Moore R-grave: Greater effect of highly active antiretroviral therapy on survival in people aged 1 or = 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003;36:212-218.
29. Skiest DJ, Keiser P: Human immunodeficiency virus infection in patients older than 50 years. A survey of primary care physicians' beliefs, practices, and knowledge. Arch Fam Med 1997;6:289-294.
30. Skiest DJ, Rubinstien E, Carley N, Gioiella L, Lyons R: The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996;101:605-611.
31. Smith C, D:A:D Study Group: Association between modifiable and non-modifiable risk factors and specific causes of death in the ART era: the data collection on adverse events of anti-HIV drugs study. 16th Conference on Retroviruses and Opportunistic Infections (abstract 145), Montréal, 2009.
32. Smith R-grave, Delpech VC, Brown AE, Rice B-grave: HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AI-graveS 2010;24:2109-2115.
33. Stall R, Catania J: AI-graveS risk behaviors among late middle-aged and elderly Americans. The National AI-graveS Behavioral Surveys. Arch Intern Med 1994;154:57-63.
34. Suligoi B, Boros S, Camoni L, Lepore D: Aggiornamento dei casi di AI-graveS notificati in Italia e delle nuove diagnosi di HIV al 31 Dicembre. Not Ist Super Sanitá 2005;18(suppl 1).
35. Sullivan AK, Curtis H, Sabin CA, Johnson MA: Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005;330:1301-1302.
36. Tumbarello M, Rabagliati R, De Gaetano DK, Bertagnolio S, Tamburrini E, Tacconelli E, Cauda R: Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AI-graveS 2003;17:128-131.
37. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren J-grave: Influence of age on C-grave4 cell recovery in human immunodeficiency virusinfected patients receiving highly active antiretroviral therapy: evidence from the Euro-SI-graveA study. J Infect Dis 2001;183:1290-1294.
38. Wellons MF, Sanders L, Edwards LJ, Bartlett JA, Heald AE, Schmader KE: HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002;50:603-607.
39. Wutoh AK, Elekwachi O, Clarke-Tasker V, Daftary M, Powell NJ, Campusano G: Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr 2003;33(suppl 2): S106-S114.